Muse Cell Therapy for Chronic Lung Disease in Newborns
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic lung disease in newborns are primarily symptomatic and lack a cure, with stem cell therapies facing challenges in differentiation ability and safety concerns, particularly with pluripotent stem cells like iPS cells due to high tumor-forming potential and complex preparation requirements.
Innovation Solution
A cell preparation comprising SSEA-3-positive pluripotent stem cells (Muse cells) isolated from mesenchymal tissue, enriched through stress treatment, which are CD105-positive and negative for specific markers, exhibiting low telomerase activity, ability to differentiate into germ layers, and self-renewal, administered intravenously to promote tissue restoration and anti-inflammatory effects in chronic lung disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If iPS cells are used for treatment of chronic lung disease, then therapeutic effect is expected, but tumor forming ability increases and preparation complexity increases
Solution Approach 1:
The patent extracts and isolates a specific subset of pluripotent stem cells (SSEA-3 positive cells) from the heterogeneous bone marrow mesenchymal cell population. This extraction process separates the desired therapeutic cells from other cell types, achieving a purer cell preparation that maintains therapeutic potential while reducing unwanted properties like tumor formation associated with broader iPS cell populations
Solution Approach 2:
The patent applies local quality by selecting cells with specific surface markers (SSEA-3 positive, CD105 positive, and negative for CD34, CD117, CD146, NG2, vWF, and CD271) to create a homogeneous cell population. This marker-based selection ensures that only cells with the desired therapeutic characteristics are used, while excluding cells with harmful properties
2Reliability
If iPS cells are used for treatment of chronic lung disease, then therapeutic effect is expected, but operation complexity increases
Solution Approach 1:
The patent simplifies the preparation process by extracting SSEA-3 positive pluripotent stem cells directly from bone marrow mesenchymal cells through flow cytometry-based separation. This approach avoids the complex reprogramming procedures required to generate iPS cells from somatic cells, significantly reducing operational complexity while maintaining therapeutic efficacy
Solution Approach 2:
The patent utilizes readily available bone marrow mesenchymal cells as a source material, which can be easily obtained and processed. This approach replaces the complex and time-consuming iPS cell generation process with a more straightforward extraction method using naturally occurring pluripotent cells in the bone marrow
3Reliability
If bone marrow mesenchymal stem cells are used, then therapeutic effect is observed, but differentiation ability is unclear and variation in therapeutic effect is huge
Solution Approach 1:
The patent segments the heterogeneous bone marrow mesenchymal cell population into distinct subsets based on surface marker expression. By isolating the SSEA-3 positive subset, the patent creates a homogeneous cell population with well-defined differentiation potential and consistent therapeutic effects, eliminating the variability observed in untreated mesenchymal cell preparations
Solution Approach 2:
The patent applies local quality by selecting cells with specific marker profiles (SSEA-3 positive, CD105 positive, and negative for other markers) to create a uniform cell population. This selection criteria ensures consistent differentiation ability and therapeutic effect across all cells in the preparation, eliminating the huge variation observed in conventional mesenchymal cell therapies
Data Source
AI summary
The purpose of the present invention is to provide a novel medical use of pluripotent stem cells (Muse cells) in the regenerative medicine area. Provided are a cell preparation and a medicinal composition for ameliorating and treating chronic lung disease in newborns, said cell preparation and medicinal composition comprising SSEA-3-positive pluripotent stem cells isolated from a mesenchymal tissue in a living body or cultured mesenchymal cells. The cell preparation according to the present invention is based on a mechanism whereby the aforesaid disease is ameliorated and treated by administering Muse cells to a subject suffering from the disease and engrafting the cells in lung tissues.